ReviewFrontiers in oncology2021
Research Progress of Bile Acids in Cancer.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Metabolomic profiling of upper GI malignancies in blood and tissue: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Long-term supplementation of exogenous bile acids enhanced growth efficacy, hematology, non-specific immunity, and intestinal histomorphology, with significant liver dysfunction in Nile tilapia fingerlings.Veterinary research communications · 2026Article
- Biological Evaluation and SAR Exploration of Bile Acid-Dihydroartemisinin Hybrids as Potential Anticancer Agents for Colorectal Cancer.Biomolecules · 2026Article
- Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities.Frontiers in pharmacology · 2026Review
- Interaction of bile acids with functionally active liver mitochondria: uncoupling activity, detergent effect, and antioxidant action.Journal of bioenergetics and biomembranes · 2025Article
- Christensenella tenuis alleviates endotoxemia and metabolic disorders via inhibition of intestinal lipopolysaccharide translocation.Science China. Life sciences · 2025Article
- Bile acid metabolism and hepatocellular carcinoma: mechanisms of drug resistance and intervention strategies.Precision clinical medicine · 2025Review
- Metabolomic Profiling of Erector Spinae Plane Block for Breast Cancer Surgery.Medicina (Kaunas, Lithuania) · 2025Article
- Single-Cell Transcriptomic Analysis Unveils Key Regulators and Signaling Pathways in Lung Adenocarcinoma Progression.Biomedicines · 2025Article
- Unlocking mRNA Vaccine Potential in Liver Cancer Treatment via Synergistic Bile Acid Modulation.Vaccines · 2025Article
- Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome.Journal of clinical medicine · 2025Review
- Gut Microbiome and Bile Acid Interactions: Mechanistic Implications for Cholangiocarcinoma Development, Immune Resistance, and Therapy.The American journal of pathology · 2025Review
- Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.Frontiers in oncology · 2025Article
- Crosstalk between bile acids and gut microbiota: a potential target for precancerous lesions of gastric cancer.Frontiers in pharmacology · 2025Review
- Metabolomics for early-stage lung adenocarcinoma: diagnostic biomarker screening.Frontiers in oncology · 2025Article
- Bile's Hidden Weapon: Modulating the Microbiome and Tumor Microenvironment.Current microbiology · 2024Review
- Sulfated Bile Acids in Serum as Potential Biomarkers of Disease Severity and Mortality in COVID-19.Cells · 2024Article
- Article
- Novel metabolic biomarker for early detection and diagnosis to the patients with gastric cardia adenocarcinoma.Cancer medicine · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bile acids (BAs) were originally known as detergents to facilitate the digestion and absorption of lipids. And our current knowledge of BAs has been extended to potential carcinogenic or cancer suppressor factors due to constant research. In fact, BAs were regarded as a tumor promoters as early as the 1940s. Differential bile acid signals emitted by various bile acid profiles can produce distinct pathophysiological traits, thereby participating in the occurrence and development of tumors. Nevertheless, in recent years, more and more studies have noticed the value of BAs as therapeutic targets. And several studies have applied BAs as a therapeutic agent for various diseases including cancer. Based on the above evidence, we acknowledge that the role of BAs in cancer has yet to be exploited, although considerable efforts have been made to probe the functions of BAs. In this review, we describe the characteristics of BAs as a double-edged sword in cancer, hoping to provide references for future cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.